



Dr. Stefanie Aepli

Medizinische Onkologie und Hämatologie · Dept. I

Contact

Dr. Stefanie Aepli

T +41 71 494 1238

Homepage

www.kssg.ch/onkologie

Units

Medizinische Onkologie und Hämatologie

Publications (12)

Wosny M, Aeppli S, Fischer S, Peres T, Rothermundt C, Hastings J. Factors Guiding Clinical Decision-Making in Genitourinary Oncology. *Cancer Med* 2024; 13:e70304.

Mokbel S, Baciarello G, Lavaud P, Omlin A, Calabrò F, Cathomas R, Aeppli S, Parent P, Giannatempo P, Koster K, Appel N, Gonnet P, Angius G, Tsantoulis P, Arkenau H, Cattrini C, Messina C, Zeghondy J, Morelli C, Lorient Y, Formica V, Patrikidou A. Development and Validation of an Inflammatory Prognostic Index to Predict Outcomes in Advanced/Metastatic Urothelial Cancer Patients Receiving Immune Checkpoint Inhibitors. *Cancers (Basel)* 2024; 16

Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. *J Cancer Res Clin Oncol* 2024; 150:84.

de Joode K, Mora A, van Schaik R, Zippelius A, van der Veldt A, Gerard C, Läubli H, Michielin O, von Moos R, Jörgen M, Levesque M, Aeppli S, Mangana J, Mangas C, Trost N, Meyer S, Parvex S, Mathijssen R, Metaxas Y. Effects of CTLA-4 Single Nucleotide Polymorphisms on Toxicity of Ipilimumab-Containing Regimens in Patients With Advanced Stage Melanoma. *J Immunother* 2024; 47:190-194.

Cathomas R, Rothschild S, Hayoz S, Bubendorf L, Özdemir B, Kiss B, Erdmann A, Aeppli S, Mach N, Strebel R, Hadaschik B, Berthold D, John H, Zihler D, Schmid M, Alborelli I, Schneider M, Musilova J, Spahn M, Petrausch U. Perioperative Chemoimmunotherapy With Durvalumab for Muscle-Invasive Urothelial Carcinoma: Primary Analysis of the Single-Arm Phase II Trial SAKK 06/17. *J Clin Oncol* 2023; 41:5131-5139.

Aeppli S, Engeler D, Fischer S, Omlin A, Pratsinis M, Hermann C, Rothermundt C. Incidence and outcome of patients with renal cell carcinoma treated with partial or radical nephrectomy in the Cantons St Gallen and Appenzell 2009-2018. *Swiss Med Wkly* 2022; 152:w30175.

Aeppli S, Rothermundt C, Sternberg C, Schmidinger M, Rini B, Porta C, Oldenburg J, McDermott D, Larkin J, Grünwald V, Escudier B, Eisen T, Schmaus M, Putora P. First-line treatment of metastatic clear cell renal cell carcinoma: a decision-making analysis among experts. *ESMO Open* 2021; 6:100030.

Moccia A, Mingrone W, Novak U, Pflieger C, Richter P, Rütli M, Schmidt A, Stenner F, Voegeli M, Zander T, Zucca E, Mey U, Lang N, Aeppli S, Güsewell S, Bargetzi M, Caspar C, Brülisauer D, Ebnöther M, Fehr M, Fischer N, Ghilardi G, Krasniqi F, Hitz F. Clinical characteristics and outcome of patients over 60 years with Hodgkin lymphoma treated in Switzerland. *Hematol Oncol* 2020; 39:196-204.

Aeppli S, Sternberg C, Schmidinger M, Rini B, Porta C, Omlin A, Oldenburg J, McDermott D, Grünwald V, Larkin J, Fischer S, Escudier B, Eisen T, Eboulet E, Rothermundt C. Impact of COVID-19 pandemic on treatment patterns in metastatic clear cell renal cell carcinoma. *ESMO Open* 2020; 5

Schmid S, Aeppli S, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort. *Lung Cancer* 2019

Schmid S, Jochum W, Demmer I, Foerbs D, Janthur W, Wannesson L, Rothschild S, Pless M, Gautschi O, Britschgi C, Aeppli S, Klingbiel D, Früh M. Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study. *Lung Cancer* 2019; 130:149-155.

Aeppli S, Driessen C, Graf L, Hitz F. Systemic treatment of a patient with relapsed and refractory extranodal NK/T-cell lymphoma (ENKL) and meningeosis leukemica with daratumumab. *Hematol Oncol* 2018

Projects (5)

Phase 2/3 Randomized Study of Tebentafusp as Monotherapy and in Combination with Pembrolizumab Versus Investigator's Choice in HLA-A*02:01-positive Participants with Previously Treated Advanced Melanoma (TEBE-AM)

Clinical Studies - Jan 26, 2024 - Dec 31, 2027

Ongoing

Muscle-invasive bladder cancer (MIBC) and perioperative treatment

Clinical Studies - May 13, 2022 - May 13, 2032

Ongoing

A PHASE II, MULTICENTRE, OPEN-LABEL STUDY OF CABOZANTINIB AS 2ND LINE TREATMENT IN SUBJECTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC RENAL CELL CARCINOMA WITH A CLEAR-CELL COMPONENT WHO PROGRESSED AFTER 1ST LINE TREATMENT WITH CHECKPOINT INHIBITORS

Clinical Studies - Jul 17, 2020 - Jul 17, 2022

Automatically Closed

A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK3475) Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone Sensitive Prostate Cancer (mHSPC) (KEYNOTE-991)

Clinical Studies - Mar 3, 2020 - Mar 10, 2030

Ongoing

A Phase 3, Randomized, Double-blind, Active-Comparator-Controlled Clinical Study of Adjuvant MK-7684A (Vibostolimab with Pembrolizumab) Versus Adjuvant Pembrolizumab in Participants with High-risk Stage II-IV Melanoma (KEYVIBE-010)

Clinical Studies - Mar 26, 23 - Dec 21, 2030

Ongoing